Evotec SE (Deutsche Börse:EVT.DE)
| Market Cap | 496.27M-59.4% |
| Revenue (ttm) | 717.28M-7.7% |
| Net Income | -197.05M-26.7% |
| EPS | -1.11-27.3% |
| Shares Out | 177.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 715,623 |
| Open | 2.88 |
| Previous Close | 2.93 |
| Day's Range | 2.79 - 2.93 |
| 52-Week Range | 2.71 - 7.30 |
| Beta | 1.27 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About EVT.DE
Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$EVT.DE stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in EVT.DE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EVT.DE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EVT.DE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New EVT.DE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EVT.DE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in EVT.DE
| ETF | Est. Holding Size |
|---|---|
| VXUSVanguard Total International Stock ETF | $8.72M |
| VEAVanguard FTSE Developed Markets ETF | $5.79M |
| IEFAiShares Core MSCI EAFE ETF | $3.65M |
| VSSVanguard FTSE All-World ex-US Small-Cap ETF | $2.63M |
| SCZiShares MSCI EAFE Small-Cap ETF | $1.55M |
| VGKVanguard FTSE Europe ETF | $1.41M |
Estimated from each fund’s disclosed top holdings × AUM
EVT.DE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from EVT.DE’s recent data — informational, not investment advice